Navigation Links
Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share
Date:11/10/2009

gment. This segment's operating income (loss) is presented as "Corporate Expense."

FORWARD-LOOKING STATEMENTS

This release may contain certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to risks, uncertainty and changes in circumstances, which may cause actual results, performance or achievements to differ materially from anticipated results, performance or achievements. All statements contained herein and in accompanying conference calls or webcasts that are not clearly historical in nature are forward-looking and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. The forward-looking statements in this release and accompanying conference calls generally include, but are not limited to, statements addressing Tyco's future financial condition and operating results, as well as its portfolio refinement activities. Economic, business, competitive and/or regulatory factors affecting Tyco's businesses are examples of factors, among others, that could cause actual results to differ materially from those described in the forward-looking statements. Tyco is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. More detailed information about these and other factors is set forth in Tyco's Annual Report on Form 10-K for the fiscal year ended Sept. 26, 2008 and in the interim reports filed on Form 10-Q for subsequent quarterly periods.

                             TYCO INTERNATIONAL LTD.
                   CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                      (in millions, except per share data)
                                   (Unaudited
'/>"/>
SOURCE Tyco International Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. Phoenix House Appoints Dr. Deni Carise as Chief Clinical Officer - Internationally Recognized Leader in Substance Abuse Treatment and Research
2. Tyco International to Present at the Citi Industrial Manufacturing & Transportation Conference
3. AirMed International, Top U.S. Air Ambulance, Receives EURAMI Accreditation
4. HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China
5. Allied Worlds Nicole Baummer and Marjorie Thompson to Speak at PLUS International Conference
6. Service Corporation International Announces Third Quarter 2009 Financial Results
7. Stenum Hospital Kicks off International Rollout of M6 Artificial Lumbar Disc Replacement Surgery
8. FDA CONSUMER HEALTH INFORMATION UPDATES: Fraudulent H1N1 flu products, hearing aids, sound amplifiers, tobacco regulation, FDAs international posts, LASIK eye surgery, and FDA MedWatch safety alerts
9. Service Corporation International Announces Schedule for Its Third Quarter 2009 Earnings Release and Conference Call
10. Blue Cross and Blue Shield of Floridas Power of the Human Voice Campaign Wins Prestigious DMA International ECHO Gold Award
11. MediSend International Joins the Clinton Global Initiative With the Afghanistan Health and Human Resource Initiative

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...od pressure readings in children with chronic kidn... during doctor,s office visits increasing a child...esearch from Johns Hopkins Children,s Center and o...s online in the Journal of American Society of Nep... measurements obtained during regular doctor visit...
(Date:11/20/2009)...nks it,s as short as 34 weeks, potentially adding ..., FRIDAY, Nov. 20 (HealthDay News) -- Recent repor...ues to climb in the United States. Now, a new stu...d about what constitutes a full-term birth in the ... surveyed in the study considered a baby born at 3...
(Date:11/20/2009)...ctivity remains high and is expected to continue, ...y News) -- Some areas of the United States are see... health official said Friday, and while the diseas...m the 46 states reported last week. , "We are b...y around the country, but there is still a lot of ...
(Date:11/20/2009)... SPRINGFIELD, Mo., Nov. 20 Missour...al Missouri regions will now have the option to ch...ched Tuesday between Missouri Consolidated Health ...e Southwest and South Central Missouri regions inc... Christian, Dade, Dallas, Douglas, Greene, Hickory...
(Date:11/20/2009)... BATON ROUGE, La., Nov. 20 /PRNewswire-USNewswir...(LAHP) today warned that Louisianians could experi...its if proposals being considered by Congress shou... executive officer for LAHP, "Louisiana health pla... since the beginning of the national debate. Our ...
Breaking Medicine News(10 mins):Health News:High blood pressure easy to miss in children with kidney disease 2Health News:Many Women Miscalculate Time to Full-Term Birth 2Health News:Many Women Miscalculate Time to Full-Term Birth 3Health News:Many Women Miscalculate Time to Full-Term Birth 4Health News:Swine Flu Declining in Some Parts of U.S. 2Health News:Swine Flu Declining in Some Parts of U.S. 3Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2Health News:Congressional Health Care Reform Proposals Would Make Health Care More Expensive, Reduce Benefits for Louisianians 2
...7 Merck & Co., Inc.,today said that it has not ye...k State and New York City seeking Medicaid reimbur...t the suit as it has defended against the,Medicaid...ug Administration (FDA) approval, and consistently...
...or Living,Inc. (NYSE: BKD ) announced today that ...sh dividend on its common stock of $0.50 per share....50 per share dividend is payable,on October 12, 2...ving facilities throughout the United States. The ...
...Biosciences,Inc. (LSE: AKR) which develops, manufa...g and testing products, is pleased to announce tha...Army for the purchase of its,BreathScan alcohol sa...gnificant,orders from several departments of the U...
... Focus on Cardiovascular Disease, Prevention and ...e Care Improvements, ...Charlie,Rose Science Series" on PBS will focus on ...l Laureate and President of,Rockefeller University...
...hat patients with cancer in the head and neck regi...kills compared with individuals without the diseas... Archives of Otolaryngology-Head & Neck Surgery, o...ork together. These functions can be compromised t...
...rday, October 20,Event to be held in honor of Octo...PLAINS, Mo., Sept. 17 GAMMILL QUILTING SYSTEMS, a...ngarm quilting systems, in,cooperation with it,s n...tional Breast Cancer Awareness Month; and in,suppo...
Other Medicine News:Health News:Merck & Co., Inc. Response to Today's New York Medicaid Suit 2Health News:Merck & Co., Inc. Response to Today's New York Medicaid Suit 3Health News:Akers Biosciences, Inc. 'ABI' or the 'Company' Receipt of Further United States Military Contracts 2Health News:Charlie Rose Science Series Explores Heart Disease 2Health News:Charlie Rose Science Series Explores Heart Disease 3Health News:Patients with head and neck cancer may have impairment of some driving skills 2Health News:'Think Pink with Gammill(R)' 2
(Date:11/20/2009)...Newswire-FirstCall/ -- Smith & Nephew ( SNN, L...ce the signing of a technology development contrac...t may lead to the creation of a fracture fixation ...the limbs of soldiers who sustain battlefield inju...ch Projects Agency (DARPA), the central research a...
(Date:11/19/2009)... BioCryst Pharmaceuticals...g of a public offering of 5,000,000 shares of its ...s proceeds of $48.75 million. All of the shares a...ive shelf registration statement previously filed ...ryst has also granted the underwriters a 30-day op...
(Date:11/19/2009)...9 /PRNewswire-Asia/ -- ScinoPharm, a leading globa...PIs), announced that its,Tainan facility has recei...SafeBridge(R) Consultants, Inc. The Certification ...n the safe handling of potent active,pharmaceutica...ratories and,production areas used for the manufac...
Breaking Medicine Technology:Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2CQ Forum on Biosimilar Biological Products Wed June 17 2009 12618 1Proteolix Inc Drug Candidate PR 957 Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome 4591 1Proteolix Inc Drug Candidate PR 957 Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome 4591 2Proteolix Inc Drug Candidate PR 957 Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome 4591 3Coming Soon 3A Lung Cancer Spray 3F 48863 1Coming Soon 3A Lung Cancer Spray 3F 48863 2
...in Long-term PASI 75, Response and Marked Improve... Study Findings, BUENOS AI...s from an international, Phase 3 study showed that... severe plaque psoriasis receiving,two doses of us...nt,reduction in psoriasis at week 12, the primary ...
...es, Inc. (Nasdaq: RMTI ), a leading, innovative m...ialty pharmaceuticals focused on the end-,stage-re... has begun dosing,patients in its Phase IIb Dose-R...hate (SFP), the Company,s physiological iron-maint...n is a double-blind, multi-center,randomized, plac...
Other Medicine Technology:Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 2Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 3Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 4Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 5Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 6Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study 2Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study 3Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study 4
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
Medicine Products: